Mitsuhiro Takemura

Dr. Mitsuhiro Takemura

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
TOTsuyoshi Ohta
Tsuyoshi Ohta
MMMasanori Morimoto
Masanori Morimoto
KOKenji Okada
Kenji Okada
MFMaki Fukuda
Maki Fukuda
HOHirokazu Onishi
Hirokazu Onishi
MTMitsuhiro Takemura
Mitsuhiro Takemura
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 May 2021 in World Neurosurgery
Verified
Journal Article
Closed access
RKRyo Kiyose
Ryo Kiyose
MSMasanori Sasaki
Masanori Sasaki
YKYuko Kataoka-Sasaki
Yuko Kataoka-Sasaki
MNMasahito Nakazaki
Masahito Nakazaki
HNHiroshi Nagahama
Hiroshi Nagahama
OHOsamu Honmou
Osamu Honmou

13 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMari Maeda-Yamamoto
Mari Maeda-Yamamoto
OHOsamu Honmou
Osamu Honmou
MSMasanori Sasaki
Masanori Sasaki
AHAkane Haseda
Akane Haseda
KHKagami-Katsuyama Hiroyo
Kagami-Katsuyama Hiroyo
JNJun Nishihira
Jun Nishihira
The purple-flesh potato (Solanum tuberosum L.) cultivar “Shadow Queen” (SQ) naturally contains anthocyanins. This randomized, double-blind, placebo-controlled study determines whether ingesting purple potatoes increases the number of mesenchymal stem cells (MSC) and improves stress response, a minor health complaint in healthy adults (registration number: UMIN000038876). A total of 15 healthy subjects (ages: 50–70 years) with minor health complaints were randomly assigned to one of two groups. For 8 weeks, the placebo group received placebo potatoes cv. “Haruka” and the test group received test potato cv. SQ containing 45 mg anthocyanin. The MSC count and several stress responses were analyzed at weeks 0 and 8 of the intake periods. The ingestion of a SQ potato did not affect the MSC count but markedly improved psychological stress response, irritability, and depression as minor health complaints compared with “Haruka”. No adverse effects were noted. Hence, an 8-week intake of SQ could improve stress responses.

6 July 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
SOShinichi Oka
Shinichi Oka
TYTomohiro Yamaki
Tomohiro Yamaki
MSMasanori Sasaki
Masanori Sasaki
RURYO UKAI
RYO UKAI
MTMitsuhiro Takemura
Mitsuhiro Takemura
OHOsamu Honmou
Osamu Honmou
Background: Brain injuries resulting from motor vehicle accidents and falls, as well as hypoxic insults and other conditions, are one of the leading causes of disability and death in the world. Current treatments are limited but include continuous rehabilitation, especially for chronic brain injury. Recent studies have demonstrated that the intravenous infusion of mesenchymal stem cells (MSCs) has therapeutic efficacy for several neurological diseases, including stroke and spinal cord injury. Objective: The objective of our investigator-initiated clinical trial is to assess the safety and potential efficacy of the intravenous infusion of autoserum-expanded autologous MSCs for patients with chronic brain injury. Methods: The (phase 2) trial will be a single-arm, open-label trial with the primary objective of confirming the safety and efficacy of autoserum-expanded autologous MSCs (STR-01; produced under good manufacturing practices) when administered to patients with chronic brain injury. The estimated number of enrolled participants is 6 to 20 patients with a modified Rankin Scale grade of 3 to 5. The assessment of safety and the proportion of cases in which the modified Rankin Scale grade improves by 1 point or more at 180 days after the injection of STR-01 will be performed after MSC infusion. Results: We received approval for our clinical trial from the Japanese Pharmaceuticals and Medical Devices Agency on December 12, 2017. The trial will be completed on June 11, 2023. The registration term is 5 years. The recruitment of the patients for this trial started on April 20, 2018, at Sapporo Medical University Hospital in Japan. Conclusions: Our phase 2 study will aim to address the safety and efficacy of the intravenous infusion of MSCs for patients with chronic brain injury. The use of STR-01 has been performed for patients with cerebral infarction and spinal cord injury, providing encouraging results. The potential therapeutic efficacy of the systemic administration of autoserum-expanded autologous MSCs for chronic brain injury should be evaluated, given its safety and promising results for stroke and spinal cord injury. Trial Registration: Japan Medical Association Center for Clinical Trials JMA-IIA00333; https://tinyurl.com/nzkdfnbc International Registered Report Identifier (IRRID): DERR1-10.2196/37898

1 January 2020 in Journal of Neuroendovascular Therapy
Verified
Journal Article
Open access
PDF file
NMNoritaka Masahira
Noritaka Masahira
TOTsuyoshi Ohta
Tsuyoshi Ohta
TTTakaya Tsuno
Takaya Tsuno
KOKenji Okada
Kenji Okada
MFMaki Fukuda
Maki Fukuda
TOTaku Okamoto
Taku Okamoto
Objective: We report two cases of acute proximal anterior circulation occlusion after pulmonary lobectomy. Case Presentation: Case 1 was a 64-year-old male who presented with occlusion of the right middle cerebral artery (MCA) one day after left lower lobectomy. Case 2 was a 68-year-old male who presented with occlusion of the right internal carotid artery (ICA). In both cases, mechanical thrombectomy was performed for complete recanalization and symptoms were improved. Conclusion: Prompt mechanical thrombectomy in the acute phase after pulmonary lobectomy improved the prognosis of patients with acute proximal anterior circulation occlusion. It is important to share information about ischemic complications with medical staff engaged in thoracic surgery.

11 March 2022 in JMIR Preprints
Verified
Preprint
Open access
SOShinichi Oka
Shinichi Oka
TYTomohiro Yamaki
Tomohiro Yamaki
MSMasanori Sasaki
Masanori Sasaki
RURYO UKAI
RYO UKAI
MTMitsuhiro Takemura
Mitsuhiro Takemura
OHOsamu Honmou
Osamu Honmou
BACKGROUND Brain injuries resulting from motor vehicle accidents and falls, as well as hypoxic insults and other conditions, are one of the leading causes of disability and death in the world. Current treatments are limited but include continuous rehabilitation, especially for chronic brain injury. Recent studies have demonstrated that the intravenous infusion of mesenchymal stem cells (MSCs) has therapeutic efficacy for several neurological diseases, including stroke and spinal cord injury. OBJECTIVE The objective of our investigator-initiated clinical trial is to assess the safety and potential efficacy of the intravenous infusion of autoserum-expanded autologous MSCs for patients with chronic brain injury. METHODS The (phase 2) trial will be a single-arm, open-label trial with the primary objective of confirming the safety and efficacy of autoserum-expanded autologous MSCs (STR-01; produced under good manufacturing practices) when administered to patients with chronic brain injury. The estimated number of enrolled participants is 6 to 20 patients with a modified Rankin Scale grade of 3 to 5. The assessment of safety and the proportion of cases in which the modified Rankin Scale grade improves by 1 point or more at 180 days after the injection of STR-01 will be performed after MSC infusion. RESULTS We received approval for our clinical trial from the Japanese Pharmaceuticals and Medical Devices Agency on December 12, 2017. The trial will be completed on June 11, 2023. The registration term is 5 years. The recruitment of the patients for this trial started on April 20, 2018, at Sapporo Medical University Hospital in Japan. CONCLUSIONS Our phase 2 study will aim to address the safety and efficacy of the intravenous infusion of MSCs for patients with chronic brain injury. The use of STR-01 has been performed for patients with cerebral infarction and spinal cord injury, providing encouraging results. The potential therapeutic efficacy of the systemic administration of autoserum-expanded autologous MSCs for chronic brain injury should be evaluated, given its safety and promising results for stroke and spinal cord injury. CLINICALTRIAL Japan Medical Association Center for Clinical Trials JMA-IIA00333; https://tinyurl.com/nzkdfnbc INTERNATIONAL REGISTERED REPORT DERR1-10.2196/37898